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Chronic graft-versus-host disease (cGVHD) is
a common cause of morbidity and mortality following
allogeneic stem cell transplantation (HCT), with ap-
proximately 50% to 60% of long-term HCT survivors
developing one or more manifestations of the disorder.
Although acute GVHD is typically limited to skin,
liver, and gastrointestinal involvement, virtually every
organ is at risk for the development of cGVHD.
Although the pathophysiology of cGVHD remains
poorly understood, someof themost severe organman-
ifestations are linked by end-organ fibrosis. In particu-
lar, fibrotic cutaneous and bronchiolar changes,
resulting in scleroderma-like changes and bronchiolitis
obliterans syndrome (BOS), respectively, are two of the
most devastating outcomes for these patients. Both
sclerotic GVHD (ScGVHD) and BOS have been
reported in 5% to 15% of patients with cGVHD [1,2].
Unfortunately, standard treatment for cGVHD
has not changed significantly in the past 30 years and
relies heavily on the use of agents that reduce the activ-
ity of alloreactive T cells. Many of the manifestations
of cGVHD however, share clinical characteristics
seen in nontransplant conditions, including systemic
sclerosis or pulmonary fibrosis. Thus, understanding
the pathophysiology underlying these related condi-
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Tyrosine kinase inhibitors (TKIs) have been
shown to inhibit two different profibrotic pathways
(transforming growth factor b [TGF-b] and
platelet-derived growth factor [PDGF]) in various
mouse models of fibrotic disease and offer a possible
novel treatment approach for cGVHD patients suf-
fering from severe sclerosis [3]. Likewise, overexpres-
sion of TNF-a has been shown to induce fibrogenesis
in experimental hepatocellular disease [4] and has
been linked with human scleroderma-associated in-
terstitial pulmonary fibrosis [5] and profibrotic re-
sponses in human osteoarthritic hip joint fibroblasts
[6]. The use of TNF antagonists has been examined
in some clinical situations associated with fibrosis
[7,8], suggesting they may also be of some benefit
to patients with cGVHD; however, this must first
be prospectively tested.LUNGCOMPLICATIONS IN LONG-TERMHCT
SURVIVORS
HCT patients are particularly vulnerable to both
non–GVHD-related and GVHD-related pulmonary
complications post-HCT, with rates of 40% to 60%
in adults [2] and as high as 70% in pediatric recipients
[9]. These complications can account for as much as
50% of transplant-related mortality. cGVHD of the
lung, manifesting as BOS, is a clinical syndrome
defined as a new fixed airflow obstruction of the small
airways that typically occurs late after allogeneic
HCT. Rates of BOS in patients that develop cGVHD
range from 7% to 16%, with a median time to diagno-
sis .400 days post-HCT [10,11]. Therefore, HCT
physicians must remain vigilant and investigate all
signs and symptoms of lung dysfunction beyond the
first year post-HCT, particularly in patients with
already established cGVHD.
The gold standard for diagnosis of bronchiolitis
obliterans relies on lung biopsy, which typically reveals
obliteration of the lumen of the terminal bronchioles
with relative sparing of the distal alveolar structures.
The bronchiolar lumen is characterized as being filled
with fibrinous tissue that may contain an inflammatory
Table 1. Proposed Modifications to NIH BOS Clinical
Definition (adapted from [14])
Absence of infection (no change)
Another cGVHD manifestation in another organ (no change)
FEV1 <75% predicted (no change) or >10% decline from pre-HCT value
(modification)
Signs of Obstruction
 FEV1/SVC ratio <0.7 (modification), or
 RV >120% predicted (no change), or
 RV/TLC >120% (modification), and
 HRCTwith evidence of air trapping (no change)
SVC indicates slow vital capacity; RV, residual volume; TLC, total lung
capacity; HRCT, high-resolution computed tomography.
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commonly seen early in the course of the disease and
usually contain neutrophils and mononuclear cells,
which ultimately leads to progressive circumferential
fibrosis of the terminal airways. Clinically, this is often
accompanied by fixed airway obstruction noted on pul-
monary function testing (PFT), leading to the diagno-
sis of clinical BOS. Despite the need to identify
histologic abnormalities, it is uncommon in clinical
practice to pursue surgical lung biopsies because of
an unacceptably high complication rate in these
patients. Recognizing this limitation, the National
Institutes of Health (NIH) published guidelines for
the clinical diagnosis of BOS without histologic con-
firmation in 2005 [13]; further refinement of these
criteria were recently proposed by Williams et al.
[14] (see Table 1). These refinements in the diagnosis
allow for correction of poor PFTs before transplant
and for identification of patients with airway obstruc-
tion that might otherwise be missed secondary to con-
comitant restrictive defects from ScGVHD or
myositis.
The pathophysiology of BOS remains elusive. BOS
is not observed in recipients of autologous transplanta-
tion [11] and is rarely the solemanifestation of cGVHD
in allogeneic HCT recipients. Therefore, BOS is pre-
sumed to be the result of donor T cell recognition of
alloantigens present in the recipient airways. This pre-
sumption is further supported by clinical and patho-
logic findings of chronic rejection in lung transplant
recipients, in whom the clinical manifestations and
pathologic findings are essentially interchangeable
with cGVHD patients. Of course, in lung transplanta-
tion recipients, the allorecognition occurs in the oppo-
site direction, with the host recognizing the graft as
nonself. Therefore, collaborations between physicians
and scientists familiar with the development of BOS,
regardless of the antecedent clinical condition, may
prove critical in advancing treatment, helping elucidate
the pathophysiology of this post-HCT complication
and offering insight into future targeted therapies.
Infectious complications are common in HCT
recipients, and the frequency increases in the setting
of cGVHD and subsequent increases in immunosup-
pression. Hence, one of the diagnostic criteria forconfirming BOS is the absence of infection, primarily
because untreated infections can also lead to obstruc-
tive airflow defects detected on PFT. In the absence
of overt signs of infection, many physicians may be
hesitant to request bronchoscopy with bronchoalveo-
lar lavage (BAL) because of concerns over procedural
complications. At the University of Michigan, we
reviewed outcomes after BAL performed from 2001
to 2008 for pulmonary dysfunction following
allogeneic transplant (Greg Yanik, personal commu-
nication). During the study period, 897 allogeneic
transplantations were performed, and in 327 cases
(36%), a BAL was required for further evaluation of
pulmonary dysfunction, which was defined as (1) clin-
ical symptoms (cough, hypoxia, or dyspnea) plus (2)
radiographic abnormalities (chest radiograph or com-
puted tomography). We found that BAL identified
a pathogenic organism only 22% of the time in pa-
tients\100 days (‘‘early’’) post-HCT, whereas patho-
genic organisms were identified in 41% of patients
.100 days (‘‘late’’) post-HCT. The most common
organisms identified in BAL procedures performed
late post-HCT were Aspergillus species (n 5 39, me-
dian time to diagnosis 362 days) and Pseudomonas spe-
cies (n 5 8, median time to diagnosis 700 days). The
overall rate of intra- or postprocedure complications
such as hypoxia leading to intubation, hemorrhage,
or hypotension was low, at only 3% (unpublished ob-
servations). These results support the need to bron-
choscopically assess new pulmonary symptoms,
radiographic changes, and/or PFT decline, because
establishing an infectious process has significant im-
pact on subsequent therapy recommendations.
Effective therapy for established BOS remains lim-
ited, with augmented immunosuppression being the
primary mode of treatment, and results are subopti-
mal. The dismal overall survival for BOS patients is
approximately 15% [11,15]. Although augmentation
of immunosuppression has been shown to help slow
the progression of BOS in lung transplantation
recipients, the results in HCT recipients have been
less encouraging, with response rates to high-dose
systemic corticosteroids (prednisone 1 mg/kg/day or
equivalent) resulting in an improvement in only 20%
of BOS patients [16]. The poor response to standard
cGVHD therapy further highlights the need for rigor-
ous clinical trials to identify potential beneficial thera-
peutic inventions for at-risk patients. The hope is that
improved screening and early intervention for BOS in
HCT patients may prevent further decline before the
patient meets the full criteria for BOS. As an example,
inhaled corticosteroids (and additional immune modi-
fiers such as montelukast and azithromycin) are cur-
rently being studied for efficacy in slowing the
progression of the disease [17].
At the University of Michigan, we observed an
approximate 25% incidence of both restrictive and
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Figure 1. Effect of etanercept on survival in post-HCT patients with
subacute lung injury. (A) Overall 5-year survival by pulmonary function
testing defect. Patients with an obstructive defect (solid line) had
a 5-year survival of 67% compared with 44% in those with a restrictive
lung defect (dashed line) (P 5 .19). (B) Overall 5-year survival by
response to therapy. Patients who responded to etanercept therapy
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emergence of restrictive lung defects occurred within 3
to 6 months post-HCT and was likely related to
regimen-associated toxicity. Obstructive defects con-
tinued to slowly increase post-HCT with rates of
14% and 23% at 1 and 2 years post-HCT, respectively,
and were more likely to be associated with cGVHD.
Based on the high rate of subacute lung injury post-
HCT, our group at University of Michigan developed
a clinical trial investigating the use of etanercept for
TNF-a inhibition for this patient population (Clini-
calTrials.gov NCT00141726). Eligible patients
needed to demonstrate .15% decline in PFTs from
pre-HCT values (defined as forced vital capacity
(FVC)\80% predicted for a restrictive defect or an
FEV1/FVC \75% predicted for an obstructive de-
fect). Additionally, all patients underwent BAL
before receiving study treatment. Fifty-seven patients
were enrolled, but 23 were excluded for infectious
(predominantly fungal) findings on BAL. The remain-
der of the patients (n 5 34) received etanercept and
serial PFTs to evaluate for response, which was defined
as a 10% improvement in the target PFT parameter.
The median FEV1 at study entry was 51% of pre-
dicted; the median FVC was 62% of predicted. The
overall response rate was approximately 33% in both
the restrictive and obstructive patient populations,
and the 5-year overall survival rate trended toward be-
ing higher in the patients with obstructive, compared
with restrictive, defects (67% versus 44%; P 5 .19)
and in those patients who responded to therapy
compared with those that did not (90% versus 55%;
P 5 .07) (Figure 1). An additional important observa-
tion was that most of the responders had been diag-
nosed with their subacute lung injury less than
2 years before study enrollment, highlighting the
importance of early identification of BOS and the
need for rapid intervention [18].(solid line) had a 5-year survival of 90% compared with 55% in patients
who failed to respond (dashed line) (P 5 .07). (Figures reprinted with
permission, Biol Blood and Marrow Trans).LESSONS LEARNED FROM LABORATORY
MODELS OF LUNG FIBROSIS
Fibrosis is the end result of numerous inflamma-
tory and infectious insults to the lung. Although a great
deal of information regarding the contributions of
soluble mediators and cellular components to lung
fibrogenesis has been elucidated, other contributors
are less well studied. One such area under intense cur-
rent investigation is the lung extracellular matrix
(ECM). Long regarded as an inert scaffolding upon
which cells sit, the ECM is now recognized as a dy-
namic tissue that imparts contextual, mechanical, and
spatial clues to cells, thereby driving phenotypic
behaviors [19]. In fibrotic disorders, deposition of
ECM is considered an endpoint; however, recent
evidence suggests that ECM also plays an active rolein lung fibrogenesis. Given the critically important
role of ECM in development (as evidenced by the
observations that transgenic animals lacking many
key ECM genes are embryonically lethal) and tissue
homeostasis (as evidenced by the development of dis-
ease in patients with known ECM gene mutations,
eg, Ehlers-Danlos syndrome in patients with muta-
tions in various collagen or collagen-modulating
genes), it follows that delineation of the mechanisms
by which ECM influences cell behavior and function
will be critical to understanding fibrotic disease patho-
genesis. Reductionist studies using cells grown on pla-
nar ECM-coated plastic dishes have been informative
in elucidating the mechanistic role of ECM in cell
biology. Yet this approach does not account for the
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environment in which cells simultaneously encounter
multiple different proteins in a three-dimensional
spatial orientation.
Lung fibrogenesis is often studied in rodent
models using intratracheal or subcutaneous exposure
to agents known to result in lung damage (such as bleo-
mycin) that induce vigorous inflammation followed by
a fibrotic response [20]. However, these models do not
recapitulate all aspects of human disease with a primary
difference being the self-limited nature of experimen-
tal lung fibrosis. Indeed, the literature abounds with
reports of various therapeutic agents that appear effec-
tive against fibrosis in rodents but that are not success-
ful when assessed in humans with clinical disease [21].
Because the bleomycin model of lung fibrosis does not
recapitulate all aspects of human lung fibrosis, our re-
search group at the University of Michigan now uses
primary human tissues to begin to address some of
the important mechanistic questions about the role
of ECM in the development of lung fibrosis. The
lung tissue model uses a series of detergent and nucle-
ase washes, resulting in a structure devoid of all cellular
and nuclear material [22,23], consisting of only the
ECM ‘‘skeleton’’ within which cells may be cultured
and assayed.
This in vitro lung tissue model has the clear advan-
tage of being clinically relevant, because the tissues are
derived from humans with the disease under study,
although a significant disadvantage is the current
inability to study effects that occur in a breathing, per-
fusing lung. It is, however, more likely to closely re-
semble the biologic conditions encountered by cells
in vivo rather than cultured in vitro on tissue culture
plastic. As evidence of clinical relevance, some investi-
gators have begun to use these decellularized matrices
as a structure into which new cells may be seeded, re-
sulting in the regeneration of functional organ tissue
[24,25]. Indeed, this approach has already been
adopted in humans as well, with the development of
bioengineered airways derived from cadaveric donors
but reseeded with recipient cellular material [23]. In
our lab, decellularized human normal and fibrotic
lungs are cored using a standard punch biopsy, fixed
in agarose, and then cut with a vibratome to generate
uniform-thickness slices that are used to support
in vitro cell culture.
Using this approach, our research group at Uni-
versity of Michigan has found that human lung ECM
retains a normal three-dimensional spatial orientation
and composition following decellularization, with nor-
mal and fibrotic human lungs being easily discernible
on the microscopic and ultramicroscopic levels. Addi-
tionally, fibrotic lung matrices are measurably stiffer
than normal lung matrices using atomic force micros-
copy, suggesting that the decellularization process
does not result in significant alteration of the structuralmakeup of the tissue. Finally, preliminary data show
that fibrotic lung matrix substantially alters normal
cellular phenotype compared with normal lungmatrix;
for example, fibrotic lung matrix was observed to im-
part a myofibroblastic, profibrotic phenotype to nor-
mal lung fibroblasts, whereas the same cells cultured
on normal lung matrix retained quiescent fibroblast
features. In total, these data suggest that decellularized
normal and fibrotic lung matrices can feasibly be used
as a culture substrate to investigate the role of ECM in
driving cellular functional and secretory phenotypes
and suggest that this approach may be extrapolated
to study other fibrotic disease states in the lung, such
as cGVHD.CHALLENGES OF CLINICALTRIAL DESIGN
AND IMPLEMENTATION IN SCGVHD
Extensive, sclerotic skin changes with superficial
or deep subcutaneous or fascial involvement are seen
in approximately 4% to 13% of patients with
cGVHD and can be a life-threatening manifestation
[26]. ScGVHD of the skin includes several cutane-
ous presentations characterized by inflammation
and progressive fibrosis of the dermis and subcuta-
neous tissues. These changes can resemble morphea,
systemic sclerosis, or eosinophilic fasciitis and may
or may not occur in the setting of concurrent over-
lying epidermal GVHD. When severe, ScGVHD
can result in contractures, severe wasting, and chest
wall restriction. Additionally, skin ulceration and
poor wound healing associated with skin fibrosis
can cause significant morbidity and increases the
risk of infection. The mean onset of sclerotic skin
changes following transplantation is late (529 days
in one study [1]), the natural history of this process
is unknown, and there are no large, published series
of patients that describe the clinical, histologic, and
evolutionary aspects of ScGVHD.
ScGVHD responds poorly to topical interventions
and is often resistant to systemic therapy [26]. Many
therapies have been employed, including calcineurin
inhibitors, steroids, antimetabolites, biologic agents,
hydroxychloroquine, and extracorporeal photophere-
sis. Responses are typically mixed and slow to occur
if seen. The risk factors, clinical markers, and mecha-
nisms of ScGVHD development remain largely
unknown despite the major impact on long-term mor-
bidity. CD31 T cell dose in the graft, eosinophilia,
positive antinuclear antibody, and antecedent non-
sclerotic cGVHD skin involvement have been pro-
posed as markers of ScGVHD [26]; however, most
studies do not distinguish between sclerotic and
nonsclerotic cutaneous manifestations of cGVHD
[26,27], making conclusions specific to ScGVHD
difficult to generalize.
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FOR SCGVHD
Development of clinical trials for patients with
cGVHD is difficult because of the complexity and het-
erogeneity of disease, variable approaches to treatment,
and the lack of standardized assessments of disease [28].
In particular, the study of ScGVHD lacks universally ac-
cepted measures of disease burden and response. Investi-
gators have used several measures to assess ScGVHD
involvement including body surface area, magnetic
resonance imaging, ultrasound, and range-of-motion
measurements. Additionally, investigators have tried to
apply theRodnan score, the standardmeasure for skin in-
volvement in scleroderma. Thus far, none of these mea-
sures has proven to be completely reliable in the setting
of ScGVHD, and it is likely that multiple measures will
need to be integrated into the assessment of ScGVHD.TKIS FOR SCGVHD
Imatinib mesylate (Gleevec in the US; Glivec in
Europe, Australia, and Latin America, marketed by
Novartis) is a TKI that has biological activity against
both PDGF and TGF-b signaling pathways. Both
cytokines have been implicated in the pathogenesis of
several fibrosing diseases, including hepatic, renal, and
lung, as well as in scleroderma, a disease that closely re-
sembles ScGVHD [29-32]. In addition, stimulatory
antibodies specific for the PDGF receptor (PDGFR)
were identified in a series of 39 patients with extensive
cGVHD with higher levels detected in those patients
with skin involvement [29]. Similar stimulatory anti-
bodies targetingPDGFRhavebeen reported inpatients
with scleroderma, suggesting an important therapeutic
target for these fibrosing conditions [30]. Imatinib
mesylate has particularly potent activity against
PDGF and is FDA approved in the United States for
the treatment of several disorders associated with aber-
rant PDGFR signaling [33-35]. The side effect profile
of the drug is well established in non-HCT patients,
which is helpful in the setting of a therapy for allogenic
HCT patients, many of whom have multiorgan system
symptoms and possible dysfunction and who will
require ongoing immunosuppressive therapy [34,35].
Imatinib mesylate has shown preclinical and clini-
cal activity in several nonmalignant fibrosing condi-
tions such as rheumatoid arthritis, renal fibrosis, and
dermal sclerosis [31,36], although a recent trial of
imatinib in patients with pulmonary fibrosis showed
no efficacy in the primary endpoint of time to
progression of pulmonary dysfunction [21]. However,
there is a report of improved pulmonary function in
an allogeneic HCT recipient with BOS treated with
imatinibmesylate for recurrent chronic myeloid leuke-
mia [37], as well as a case series reporting lowerGVHD
incidence in post-HCT patients receiving imatinibmesylate [38]. In 2009, two separate pilot studies of
imatinib mesylate reported promising results in
ScGVHD [39,40]. Several larger studies are currently
ongoing and nearing completion in the United States.
At the NIH, we enrolled 24 patients into a trial of
imatinib mesylate for severe ScGVHD. Although
final analysis is ongoing, in general, imatinib was
poorly tolerated in this patient population, and all
patients required dose reduction in order to remain
on-study. No patients had complete resolution of scle-
rosis, butmany patients improved their ROM; imatinib
proved to be steroid sparing for many patients as well.
Because of early enthusiasm of TKI therapy,
industry-funded studies of another TKI, nilotinib,
are currently underway at various institutions (eg,
ClinicalTrials.gov NCT01155817). If these results
look promising, there is the potential for expansion
within a larger network such as the Chronic GVHD
Consortium or the BMT Clinical Trials Network.OTHER ANTIFIBROTIC AGENTS
Future therapeutic interventions for cGVHD may
be discovered among experimental agents currently be-
ing evaluated and showing preliminary success in exper-
imental models of hepatic and renal fibrosis. As
mentioned previously, TGF-b plays a central role in fi-
brogenesis, and investigators are evaluating the use of
agents that block or inhibit TGF-b signaling, such as
the small molecule decorin, halofuginone, and pirfeni-
done [41-43]. Pirfenidone is a novel antifibrotic, anti-
inflammatory, antioxidant drug that inhibits fibroblast
growth and collagen synthesis.Themechanismof action
of pirfenidone is thought to occur primarily through its
inhibition of proinflammatory cascades induced by
members of the TNF-a cytokine superfamily. Pirfeni-
done has been successfully used in patients with various
autoimmune disorders and fibrotic states; however,
despite encouraging initial results in patients with idio-
pathic pulmonary fibrosis [43], larger prospective trials
have been unable to replicate the results [44]. The fact
thatpirfenidone iswell tolerated and lacks significant im-
munosuppressive side effects could make it an especially
attractive agent for evaluation in patients with cGVHD.
Currently, the likelihood of reversing long-
standing sclerotic or fibrotic manifestations of
cGVHD is quite low, and prevention and early detec-
tion is key. Better prospective studies are needed to
help identify the risk factors for the development of
sclerosis and hopefully identify the causes in order to
prevent this difficult complication.CONCLUSIONS
The pathophysiology of the various manifestations
of cGVHD remains elusive, but improvements in the
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ConsensusCriteria in 2005 have helped facilitate clinical
trials in assessing thenatural historyof thedisease, aswell
as determine meaningful response to therapy. Through
the efforts of the Chronic GVHD Consortium, led by
Stephanie Lee at the Fred Hutchinson Cancer Research
Center, there is a multicenter, ongoing prospective
evaluation of the NIH diagnostic and assessment tools.
This effort has already resulted in several publications
[45-47] that have further refined essential criteria for
cGVHDevaluation, including organ-specificmanifesta-
tions such as BOS and ScGVHD. Currently, the Con-
sortium is conducting a multicenter prospective clinical
trial of fluticasonepropionate, azithromycin, andmonte-
lukast for the treatment of BOS (ClinicalTrials.gov
NCT01307462); a separate trial of imatinib versus ritux-
imab for treatment of ScGVHDis also enrolling subjects
(ClinicalTrials.gov NCT01309997).
Although cGVHD remains a significant problem
for many long-term survivors of HCT, critical
advances in cGVHD research and treatment can be
achieved by cooperative group efforts such as those
put forth by the Chronic GVHD Consortium and
the Clinical Trials Network.ACKNOWLEDGMENT
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